Dualitybio and Genentech entered a collaboration and license agreement to develop next-generation antibody-drug conjugates using Dualitybio’s proprietary DUPAC platform. The partnership is designed to extend ADC payload delivery beyond conventional constraints by leveraging Dualitybio’s conjugation chemistry. The agreement links Genentech’s late-stage development capabilities with Dualitybio’s platform work, aiming to progress DUPAC-based ADCs across selected targets. For ADC developers, differentiation increasingly depends on payload stability and controllable release profiles, not only binding specificity. The deal signals continuing interest from major pharma in platform-enabled ADC engineering as companies seek to improve therapeutic index and expand usable targets.